118 related articles for article (PubMed ID: 11041453)
21. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma.
Tonacchera M; Chiovato L; Pinchera A; Agretti P; Fiore E; Cetani F; Rocchi R; Viacava P; Miccoli P; Vitti P
J Clin Endocrinol Metab; 1998 Feb; 83(2):492-8. PubMed ID: 9467563
[TBL] [Abstract][Full Text] [Related]
22. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma.
Nakada K; Katoh C; Kanegae K; Tsukamoto E; Shiga T; Mochizuki T; Itoh K; Tamaki N
J Nucl Med; 1998 May; 39(5):807-10. PubMed ID: 9591580
[TBL] [Abstract][Full Text] [Related]
23. Non-hyperfunctioning nodules from multinodular goiters: a minor role in pathogenesis for somatic activating mutations in the TSH-receptor and Gsalpha subunit genes.
Derrien C; Sonnet E; Gicquel I; Le Gall JY; Poirier JY; David V; Maugendre D
J Endocrinol Invest; 2001 May; 24(5):321-5. PubMed ID: 11407651
[TBL] [Abstract][Full Text] [Related]
24. Sensitive Sequencing Analysis Suggests Thyrotropin Receptor and Guanine Nucleotide-Binding Protein G Subunit Alpha as Sole Driver Mutations in Hot Thyroid Nodules.
Stephenson A; Eszlinger M; Stewardson P; McIntyre JB; Boesenberg E; Bircan R; Sancak S; Gozu HI; Ghaznavi S; Krohn K; Paschke R
Thyroid; 2020 Oct; 30(10):1482-1489. PubMed ID: 32284013
[No Abstract] [Full Text] [Related]
25. Prevalence of TSH receptor and Gsalpha mutations in 45 autonomously functioning thyroid nodules in Japan.
Nishihara E; Amino N; Maekawa K; Yoshida H; Ito M; Kubota S; Fukata S; Miyauchi A
Endocr J; 2009; 56(6):791-8. PubMed ID: 19550078
[TBL] [Abstract][Full Text] [Related]
26. G protein and thyrotropin receptor mutations in thyroid neoplasia.
Esapa C; Foster S; Johnson S; Jameson JL; Kendall-Taylor P; Harris PE
J Clin Endocrinol Metab; 1997 Feb; 82(2):493-6. PubMed ID: 9024242
[TBL] [Abstract][Full Text] [Related]
27. Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features.
Arturi F; Capula C; Chiefari E; Filetti S; Russo D
Exp Clin Endocrinol Diabetes; 1998; 106(3):234-6. PubMed ID: 9710366
[TBL] [Abstract][Full Text] [Related]
28. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.
Lazar V; Bidart JM; Caillou B; Mahé C; Lacroix L; Filetti S; Schlumberger M
J Clin Endocrinol Metab; 1999 Sep; 84(9):3228-34. PubMed ID: 10487692
[TBL] [Abstract][Full Text] [Related]
29. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
30. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
31. Similar prevalence of somatic TSH receptor and Gsalpha mutations in toxic thyroid nodules in geographical regions with different iodine supply in Turkey.
Gozu HI; Bircan R; Krohn K; Müller S; Vural S; Gezen C; Sargin H; Yavuzer D; Sargin M; Cirakoglu B; Paschke R
Eur J Endocrinol; 2006 Oct; 155(4):535-45. PubMed ID: 16990652
[TBL] [Abstract][Full Text] [Related]
32. Hot microscopic areas of iodine-deficient euthyroid goitres contain constitutively activating TSH receptor mutations.
Krohn K; Wohlgemuth S; Gerber H; Paschke R
J Pathol; 2000 Sep; 192(1):37-42. PubMed ID: 10951398
[TBL] [Abstract][Full Text] [Related]
33. Insights from molecular pathways: potential pharmacologic targets of benign thyroid nodules.
Eszlinger M; Jaeschke H; Paschke R
Curr Opin Endocrinol Diabetes Obes; 2007 Oct; 14(5):393-7. PubMed ID: 17940470
[TBL] [Abstract][Full Text] [Related]
34. Effect of lithium and oral thyrotrophin-releasing hormone (TRH) on serum thyrotrophin (TSH) and radioiodine uptake in patients with well differentiated thyroid carcinoma.
Ang ES; Teh HS; Sundram FX; Lee KO
Singapore Med J; 1995 Dec; 36(6):606-8. PubMed ID: 8781630
[TBL] [Abstract][Full Text] [Related]
35. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneous distribution of thyrotrophin receptor messenger ribonucleic acid (TSH-R mRNA) in papillary thyroid carcinomas detected by in situ hybridization.
Tanaka K; Inoue H; Miki H; Komaki K; Monden Y
Clin Endocrinol (Oxf); 1996 Mar; 44(3):259-67. PubMed ID: 8729520
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of TSHR/Gsα mutation-negative clonal hot thyroid nodules (HNs) in a Turkish cohort.
Sancak S; Jaeschke H; Eren F; Tarcin O; Guellueoglu B; Sen LS; Sever Z; Gozu HI; Bircan R; Akalin S; Paschke R; Eszlinger M
Horm Metab Res; 2011 Jul; 43(8):562-8. PubMed ID: 21773967
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of activating thyrotropin receptor and Gsα gene mutations in paediatric thyroid toxic adenomas: a multicentric Italian study.
Agretti P; Segni M; De Marco G; Ferrarini E; Di Cosmo C; Corrias A; Weber G; Larizza D; Calcaterra V; Pelizzo MR; Cesaretti G; Vitti P; Tonacchera M
Clin Endocrinol (Oxf); 2013 Nov; 79(5):747-9. PubMed ID: 23346880
[No Abstract] [Full Text] [Related]
39. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter.
Tonacchera M; Agretti P; Chiovato L; Rosellini V; Ceccarini G; Perri A; Viacava P; Naccarato AG; Miccoli P; Pinchera A; Vitti P
J Clin Endocrinol Metab; 2000 Jun; 85(6):2270-4. PubMed ID: 10852462
[TBL] [Abstract][Full Text] [Related]
40. Primary culture of cells from hyperfunctioning thyroid adenoma with an activating mutation of G alphas.
Kamiya Y; Murakami M; Yanagita Y; Koitabashi H; Nagamachi Y; Hosoi Y; Ogiwara T; Mizuma H; Iriuchijima T; Mori M
Mol Cell Endocrinol; 1998 Mar; 138(1-2):137-42. PubMed ID: 9685222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
